2025 Original Papers / 2025 原著論文
- S. Srinivasan, I. Koyanagi, P. Vergara, Y. Wang, A. Ohba, T. Naoi, K. E. Vogt, Y. Chérasse, N. Kutsumura, T. Sakurai, T. Tezuka, M. Sakaguchi
“Transient reactivation of small ensembles of adult-born neurons during REM sleep supports memory consolidation in mice”
Nat. Commun. 2025, accepted. - T. Sugai, K. Nakamura, N. Kutsumura
“Practical and unified synthesis of prenylated phenylpropanoids via O-reverse prenylation/Claisen rearrangement”
Chem. Lett. 2025, 54, upaf105. (web) - T. Yoshioka, S. Kimiki, M. Yamazaki, T. Hamano, M. Ou, Y. Ode, R. Ehara, K. Kajino, S. Kasai, K. Yoshizawa, T. Saitoh, D. Yamada, H. Nagase, A. Saitoh
“Agonists of the opioid δ-receptor improve irritable bowel syndrome-like symptoms via the central nervous system”
Br. J. Pharmacol. 2025, 182, 1599-1609. (web) - T. Yoshioka, D. Yamada, A. Hagiwara, K. Kajino, K. Iio, T. Saitoh, H. Nagase, A. Saitoh
“Delta opioid receptor agonists activate PI3K–mTORC1 signaling in parvalbumin-positive interneurons in mouse infralimbic prefrontal cortex to exert acute antidepressant-like effects”
Mol. Psychiatry 2025, 30, 2038-2048. (web) - K. Kajino, T. Sugai, T. Kakumoto, R. Kise, R. Suzuki, A. Tokuda, Y. Sekiya, R. Katamoto, N. Kutsumura, Y. Nagumo, T. Hirokawa, A. Inoue, T. Saitoh
“Structure–Signal Relationships of the δ-Opioid-Receptor (DOR)-Selective Agonist KNT-127—Part II: Quinoline Ring Modifications for Enhanced G-Protein Signaling and Reduced β-Arrestin Recruitment”
Chem. Pharm. Bull. 2025, 73, 336-348. (web) - K. Kajino, T. Sugai, R. Kise, R. Suzuki, A. Tokuda, Y. Sekiya, T. Kakumoto, R. Katamoto, N. Kutsumura, Y. Nagumo, A. Inoue, T. Saitoh
“Structure–Signal Relationships of the δ-Opioid-Receptor (DOR)-Selective Agonist KNT-127—Part I: Impact of the Morphinan Skeleton on the G-Protein-Biased DOR Agonism”
Chem. Pharm. Bull. 2025, 73, 246-256. (web) - T. Yoshioka, S. Kimiki, M. Yamazaki, T. Hamano, M. Ou, Y. Ode, R. Ehara, K. Kajino, S. Kasai, K. Yoshizawa, T. Saitoh, D. Yamada, H. Nagase, A. Saitoh
“Agonists of the opioid δ‐receptor improve irritable bowel syndrome‐like symptoms via the central nervous system”
Br. J. Pharmacol. 2025, 182, 1599-1609. (web) - K. Arai, Y. Ono, N. Hirai, Y. Sugiura, K. Kaneko, S. Matsuda, K. Iio, K. Kajino, T. Saitoh, F-Y. Wei, H. Katagiri, A. Inoue
“Chemogenetic activation of hepatic G12 signaling ameliorates hepatic steatosis and obesity”
BBA-Molecular Basis of Disease, 2025, 1871, 167566. (web)
